Your search found 2 Results
Consultative meeting on: "Accelerating an HIV / AIDS vaccine for developing countries: How can international development agencies help? South Africa, Tuesday, July 27, 1999.
[Unpublished] 1999. 11 p.On July 27, 1999, the South African Medical Research Council hosted a consultative meeting on ways in which international agencies could accelerate development of an AIDS vaccine that is effective and affordable for developing countries. 37 senior policy-makers from South Africa and the region, South African researchers, and other stakeholders participated in the meeting. The issues paper, "Accelerating an AIDS vaccine for developing countries: Issues and Options for the World Bank," and the report of the European Union (EU) Brussels Vaccine Consultation served as background for the meeting. Issues regarding the global status and prospects of HIV/AIDS vaccine development, the South Africa AIDS Vaccine Initiative, the analysis of the business costs and response of a major South African employer, the results of the industry study and issues in estimating potential demand, and the options the World Bank and EU are considering were emphasized in the meeting.
Issues related to scientific, technical, population, and behavioral preparation in WHO-selected sites.
In: International Symposium on Biomedical Research Issues of HIV Infection in Thailand. Bangkok, Thailand, January 31 - February 2, 1994. Sponsors: Thailand Health Research Institute, Harvard AIDS Institute, Ministry of Public Health of Thailand, Center for Vaccine Development, Mahidol University. Cambridge, Massachusetts, Harvard AIDS Institute, 1994. 23-4.For the past three years, the World Health Organization (WHO) has been working with national authorities and scientists from the four countries which have been identified as appropriate for the establishment of WHO-sponsored sites for HIV vaccine evaluation: Brazil, Rwanda, Thailand, and Uganda. National plans for HIV vaccine development and evaluation have been prepared by the countries and endorsed by the WHO. The plans detail the national policy and nationally acceptable guidelines for the approval and initiation of HIV vaccine-related activities. They provide specific recommendations for the selection of participating institutions, for interactions with other national and international AIDS research programs, for infrastructure strengthening, and for training and specific research activities. In preparation for phase III vaccine efficacy trials, the following priority research areas have been identified: virologic, clinical, epidemiologic, and sociobehavioral research. Research in these areas is discussed. It is also important to develop a comprehensive public information strategy to help maintain community support and political commitment. Finally, trials must be conducted with only the highest ethical standards.